Last reviewed · How we verify

Iodine I 124 Monoclonal Antibody M5A

City of Hope Medical Center · Phase 1 active Biologic

Iodine I 124 Monoclonal Antibody M5A is a Biologic drug developed by City of Hope Medical Center. It is currently in Phase 1 development. Also known as: 124I-M5A, Iodine I 124 Anti-CEA Monoclonal Antibody M5A.

At a glance

Generic nameIodine I 124 Monoclonal Antibody M5A
Also known as124I-M5A, Iodine I 124 Anti-CEA Monoclonal Antibody M5A
SponsorCity of Hope Medical Center
ModalityBiologic
PhasePhase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Iodine I 124 Monoclonal Antibody M5A

What is Iodine I 124 Monoclonal Antibody M5A?

Iodine I 124 Monoclonal Antibody M5A is a Biologic drug developed by City of Hope Medical Center.

Who makes Iodine I 124 Monoclonal Antibody M5A?

Iodine I 124 Monoclonal Antibody M5A is developed by City of Hope Medical Center (see full City of Hope Medical Center pipeline at /company/city-of-hope-medical-center).

Is Iodine I 124 Monoclonal Antibody M5A also known as anything else?

Iodine I 124 Monoclonal Antibody M5A is also known as 124I-M5A, Iodine I 124 Anti-CEA Monoclonal Antibody M5A.

What development phase is Iodine I 124 Monoclonal Antibody M5A in?

Iodine I 124 Monoclonal Antibody M5A is in Phase 1.

Related